HQ Staff Writer
March 13, 2026: Researchers have developed a promising new class of antibiotic, EVG7, an experimental glycopeptide to treat gut infection, Clostridioides difficile (C. diff).
Earlier, the standard treatment for the dangerous C. diff was powerful antibiotics like vancomycin that kill the toxic bacteria but also wipe out the vast, beneficial community of gut microbes that normally protects us. This destruction often backfires, creating a vacuum that allows C. diff to return, sometimes more aggressively, in a cycle of recurrent infections that are harder to treat .
The newly developed antibiotic EVG7, created by Professor Nathaniel Martin’s research group at the Institute of Biology Leiden (IBL), offers a potential alternative. EVG7 is a modified and more powerful version of the widely used antibiotic vancomycin.
EVG7 is designed to be “microbiome-friendly.” Early studies, led by teams at institutions like Leiden University, show it can effectively eliminate C. diff while leaving the crucial protective bacteria largely intact .
C. diff infections are a major hospital-acquired threat, causing severe diarrhea and colitis, particularly in patients who have recently taken broad-spectrum antibiotics. These initial antibiotics disrupt the gut’s microbial balance, allowing C. diff to overgrow and produce toxins . The resultant loss of microbial diversity is directly linked to the high recurrence rates of 15-30% in patients, and many experience multiple episodes. Each recurrence is more severe and costly, creating a significant burden on patients and healthcare systems.
EVG7
EVG7 represents a shift from the “scorched earth” approach of traditional antibiotics. In laboratory and mouse model studies, it demonstrated potent activity against C. diff but showed minimal inhibitory effects on a wide range of common, beneficial gut bacteria . The key finding, published in a detailed primary research article, is that EVG7 selectively spares members of the Lachnospiraceae family. This family of bacteria is a cornerstone of a healthy gut; they ferment dietary fiber into protective short-chain fatty acids like butyrate, which strengthen the gut lining and reduce inflammation, the defenses that C. diff exploits.
How it spares the ‘Good Guys’
The selectivity appears to be linked to EVG7’s unique chemical structure as a glycopeptide and its specific mechanism of action, which may target features more prominent in C. diff’s cell wall. In mouse studies, a low dose of EVG7 given prophylactically (before infection) or therapeutically (after infection) led tosignificantly lower C. diff burden in the gut (about one-third of the level in untreated mice) 4. It dramatically reduced toxin production and improved survival rates by 80% vs. 40% in controls 4.
Critically, analysis of the gut microbiome showed that EVG7 treatment preserved microbial diversity and specifically maintained high levels of Lachnospiraceae and other beneficial taxa. This contrasts sharply with vancomycin, which causes a profound and lasting collapse in microbial diversity.
The implications are substantial. By protecting the microbiome, EVG7 could prevent recurrent infections, reduce reliance on Fecal Microbiota Transplantaton (FMT).
While FMT is highly effective in preventing recurrent infections, it carries risks (pathogen transfer, lack of standardization) and is a complex procedure. A microbiome-sparing antibiotic could be a simpler, safer first-line option.
The road ahead
It’s important to note that EVG7 is still in the preclinical, experimental stage. The promising results come from sophisticated mouse models. The critical next steps are human clinical trials to confirm safety, optimal dosing, and efficacy in patients. Researchers also need to understand the full long-term effects on the human microbiome and ensure no resistance develops. However, the concept is validated and has generated significant excitement.